Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00259064
Status:
COMPLETED
Last Update Posted:
2016-06-02
First Post:
2005-11-25
Brief Title:
Iressa v BSC Best Supportive Care in First Line NSCLC
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Phase II Multicentre Randomised Parallel Group Double-Blind Placebo-Controlled Study of ZD1839 IRESSATM 250MG Tablet Plus Best Supportive Care BSC Versus Placebo Plus BSC in Chemotherapy-Naive Patients With Advanced Stage IIIB or IV Non-Small Cell Lung Cancer NSCLC and Poor Performance Status
Status:
COMPLETED
Status Verified Date:
2016-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
INSTEP
Brief Summary:
The purpose of the study is to determine if the addition of Iressa to Best Supportive Care treatment will increase the progression free survival of chemo-naïve poor performance status patients with stage IIIB or IV NSCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| D7913C00711 | None | None | None |